Massimo Offidani

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)

Gastone Castellani, Daniel Remondini, Giovanni Martinelli, 2015, Oncotarget.

Design and Methods

L. Pagano, F. Aversa, M. Caira, 2022 .

Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma.

Pietro Leoni, Francesco Alesiani, P. Galieni, 2006, Blood.

Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study

Giuseppe Leone, Giorgina Specchia, Chiara de Waure, 2010, Haematologica.

Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

Mario Boccadoro, Pierfrancesco Tassone, Laura Mosca, 2013, Clinical Cancer Research.